medline.ch Dermatologie Psoriasis

	Control of Inflammation and Sustained Improvements in Patient-Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two-Year Results From Two Phase 3 Studies. ACR Open Rheumatol Gossec L, Tillett W, Coates LC, Mease PJ, de Wit M, Gladman DD, Orbai AM, Proft F, Ink B, Bajracharya R, Lambert J, Healy P, Husni ME. PMID: 42152504 [PubMed]
	Causality analysis of fatty acids, triglycerides and psoriasis based on Mendelian randomization. Medicine (Baltimore) Long J, Deng C, Huang M, Tang L, Li Q, Wang F, Lin Y. PMID: 42152394 [PubMed - indexed for MEDLINE]
	Cutaneous Manifestations in Psoriatic Arthritis: Phenotypes, Clinical Burden, and Therapeutic Implications. Rheumatol Ther Tsafis K, Skepastianos V, Skouvaklidou E, Deligeorgakis D, Boutel M, Kontonikola A, Papazoglou N, Fragoulis GE, Kougkas N. PMID: 42151579 [PubMed - as supplied by publisher]
	Psoriasis in skin of color: clinical presentation, diagnostic challenges, and therapeutic considerations. An Bras Dermatol Costa A, Romiti R. PMID: 42150334 [PubMed - as supplied by publisher]
	An update on the safety of biologics for the treatment of psoriasis. Expert Opin Drug Saf McGuirt V, Patel H, Davis M, Feldman S. PMID: 42149685 [PubMed - as supplied by publisher]
	Biotics: The Food Ingredients Supporting the Intestinal Microbiota and Immune System in Psoriasis. Nutr Rev De Biasi J, Giménez Bastida JA, Krupa-Kozak U. PMID: 42148824 [PubMed - as supplied by publisher]
	Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel topical immunomodulatory therapy for psoriasis: bridging the therapeutic gap in moderate disease. Extracell Vesicles Circ Nucl Acids Tan TT, Tan KH, Lim SK. PMID: 42148284 [PubMed]
	Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice. Front Immunol Tang Z, Wu J, Dong M, Li C, Wang R. PMID: 42148093 [PubMed - indexed for MEDLINE]
	Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study. Psoriasis (Auckl) Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Daudén E, Weger W, Maul JT, Naldi L, Ghislain PD, Laws PM, De Jong EMGJ, Mburu S, Koscielny V, Massana E, Sapena V, Domenech A, Kasujee I, Augustin M. PMID: 42146323 [PubMed]
	Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled Trial. J Am Acad Dermatol Soung J, Lebwohl MG, Hebert A, Pink AE, Shi Y, Hong HC, Iaconangelo C, Miller-Kassamali M, Cafone J, DeKlotz CMC, Jiang J, Li S, Yang YW, Eichenfield L. PMID: 42144198 [PubMed - as supplied by publisher]
	Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial. Dermatol Ther (Heidelb) Magnolo N, Soung J, Frew J, Costanzo A, Ruiz-Santiago H, Eyerich K, Llamas-Velasco M, Bukhalo M, Sivamani RK, Moore A, Wu T, Xie J, Patel M, Ashley D, Kaplan B, Stakias V, Espaillat R, Warren RB. PMID: 42143644 [PubMed - as supplied by publisher]
	Musculoskeletal and nail ultrasound findings in children with psoriasis: a case-control study. Pediatr Rheumatol Online J Nedorezov L, Avar-Aydin PO, Ting TV, Bayart C, Cassedy A, Vega-Fernandez P. PMID: 42143389 [PubMed - as supplied by publisher]
	Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial. Dermatol Ther (Heidelb) Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. PMID: 42143206 [PubMed - as supplied by publisher]
	Inflammatory bowel disease and psoriasis as causal drivers of psychiatric disorders: A two-stage Mendelian randomization study grounded in the gut-brain-skin axis. J Affect Disord Li H, Guo Y, Zhang Z, Yang J, Li Y, Fu X, Yang S. PMID: 42142759 [PubMed - as supplied by publisher]
	Impact of a Novel Electronic Monitor on Psoriasis Patient Adherence to Prescribed Dose Frequency and Amount: Secondary Analysis of a Randomized Trial. J Am Acad Dermatol Shaffer BR, Lovell KK, Greenzaid JD, Zaino M, Subramanian V, Sirdeshmukh D, Wiegandt N, Richardson I, Feldman SR. PMID: 42142592 [PubMed - as supplied by publisher]
	Assessing the Completeness of Adverse Event Reporting in Clinical Trials of Psoriasis Treatments: A Registry-Publication Comparison Study. Clin Drug Investig Rowe M, Dinh M, Sherry R, Keefer K, Hazlitt R, Elghzali A, Archer D, Ford AI, Vassar M. PMID: 42142276 [PubMed - as supplied by publisher]
	Risk of type 2 inflammation-related diseases during Interleukin-17-inhibitors treatment for psoriasis patients-A retrospective cohort study. Br J Dermatol Li B, Han Y, Sun C, Shi M, Ran X, Wang Y, Shu D, Zhao Y. PMID: 42141899 [PubMed - as supplied by publisher]
	Systematic review and network meta-analysis of biologics and small molecules for scalp psoriasis. J Eur Acad Dermatol Venereol Lai IC, Lee KC, Huang GL, Wu PY. PMID: 42141519 [PubMed - as supplied by publisher]
	Exploring biomarkers for treatment response in psoriatic arthritis: a focus on multi-omics technologies. Pharmacogenomics J Khasru MR, Abdul Jalil NA, Nair N, Barton A, Martin P, Ho P, Bluett J. PMID: 42140907 [PubMed - indexed for MEDLINE]
	Unsaturated fatty acids mediate the bidirectional link between psoriasis and depression: Evidence from observational and mendelian randomization studies. J Dermatol Sci Chu M, Tian B, Zhou J, Xu G, Gu Y, Wang J, Hao J, Dang E, Shao S, Wang G. PMID: 42140827 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 27930

Seite 1 von 1397

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung